Literature DB >> 23906779

[Clinical, laboratory, radiological features, and outcome in 26 patients with aortic involvement amongst a case series of 63 patients with giant cell arteritis].

A Daumas1, P Rossi2, F Bernard-Guervilly2, Y Francès2, J Berbis3, J-M Durand4, G Kaplanski4, M Ebbo4, J-R Harlé4, P-J Weiller5, J Serratrice5, P Disdier5, S Gayet6, P Villani6, B Granel2.   

Abstract

PURPOSE: Aortic involvement that occurs in temporal arteritis is probably underestimated because it is usually asymptomatic. The characteristics of giant cell arteritis with aortic involvement are still poorly described and the relationship between aortitis and vascular outcome of the disease has not been clearly delineated. The objective of this retrospective study of 63 patients with giant cell arteritis, including 26 with aortic involvement, was to compare the features of patients with and without aortitis, and to assess the contribution of CT-scan and FDG-PET-scan in screening for vascular disease, monitoring, and therapeutic management of patients.
METHODS: This retrospective study was conducted in the internal medicine department of the university hospital in Marseille, France, from January 1, 2005 to September 30, 2011. Patients had at least three out of the five American College of Rheumatology criteria for temporal arteritis and aortic involvement was investigated in all patients using CT-scan. Aortic wall thickness greater or equal to 3mm was considered to be abnormal.
RESULTS: Of 63 patients diagnosed with giant cell arteritis, 26 (41.3%) had aortic involvement diagnosed by aortic CT-scan. Age at diagnosis was significantly younger (66.8 vs 73.8 years; P=0.002) in the group with aortitis. Inflammatory dorsal and low back pain, signs of vascular disease of the upper limbs (P=0.009), and higher level of acute phase reactants were associated with aortitis. Aneurysmal lesions of the aorta were significantly more frequent in the group with aortitis. Twenty patients had both aortic CT-scan and FDG-PET-scan. For patients in whom aortic involvement was not demonstrated with CT-scan, FDG-PET-scan was always non-contributive. With corticosteroids, aortitis resolved within 6 months in all patients as evaluated by aortic CT-scan. However, aortitis persisted in 80% of cases at 6 months when evaluated with FDG-PET-scan, and in 66% of cases at 12 months, without influencing the treatment.
CONCLUSION: This case series shows no specific features of aorta and its main roots involvement in giant cell arteritis, justifying a systematic screening by CT-scan. The high frequency of this arterial involvement could help physicians in the diagnosis of giant cell arteritis. Aortitis seems to be associated with vascular complications as highlighted by the frequency of aortic aneurysm and a case of early aortic dissection. Finally, the role of PET-CT-scan for screening vascular disease and therapeutic monitoring remains to be clarified.
Copyright © 2013 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  (18F)fluorodeoxyglucose positron emission tomography; Angioscanner; Aortite; Aortitis; Artérite à cellules géantes; Computed tomography scan; Giant cell arteritis; Large vessel vasculitis; Maladie de Horton; Tomographie par émission de positons au (18)fluorodéoxyglucose; Vascularite des gros vaisseaux

Mesh:

Year:  2013        PMID: 23906779     DOI: 10.1016/j.revmed.2013.06.007

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  7 in total

1.  Giant-cell arteritis: concordance study between aortic CT angiography and FDG-PET/CT in detection of large-vessel involvement.

Authors:  Hubert de Boysson; Anael Dumont; Eric Liozon; Marc Lambert; Jonathan Boutemy; Gwénola Maigné; Nicolas Martin Silva; Audrey Sultan; Kim Heang Ly; Nicolas Aide; Alain Manrique; Boris Bienvenu; Achille Aouba
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-24       Impact factor: 9.236

2.  Fever of unknown origin, giant cell arteritis, and aortic dissection.

Authors:  K Hofheinz; S Bertz; J Wacker; G Schett; B Manger
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

Review 3.  Giant cell arteritis: ophthalmic manifestations of a systemic disease.

Authors:  Elisabeth De Smit; Eoin O'Sullivan; David A Mackey; Alex W Hewitt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-05       Impact factor: 3.117

Review 4.  The role of 18F-FDG PET/CT in large-vessel vasculitis: appropriateness of current classification criteria?

Authors:  H Balink; R J Bennink; B L F van Eck-Smit; H J Verberne
Journal:  Biomed Res Int       Date:  2014-08-14       Impact factor: 3.411

5.  18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: A multicenter cohort of 130 patients.

Authors:  Hubert de Boysson; Eric Liozon; Marc Lambert; Jean-Jacques Parienti; Nicolas Artigues; Loïk Geffray; Jonathan Boutemy; Yann Ollivier; Gwénola Maigné; Kim Ly; Damien Huglo; Eric Hachulla; Pierre-Yves Hatron; Achille Aouba; Alain Manrique; Boris Bienvenu
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

6.  Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.

Authors:  Sara Monti; Ana F Águeda; Raashid Ahmed Luqmani; Frank Buttgereit; Maria Cid; Christian Dejaco; Alfred Mahr; Cristina Ponte; Carlo Salvarani; Wolfgang Schmidt; Bernhard Hellmich
Journal:  RMD Open       Date:  2019-09-16

7.  Large-vessel involvement is predictive of multiple relapses in giant cell arteritis.

Authors:  Donatienne de Mornac; Olivier Espitia; Antoine Néel; Jérôme Connault; Agathe Masseau; Alexandra Espitia-Thibault; Mathieu Artifoni; Aurélie Achille; Anaïs Wahbi; Mathieu Lacou; Cécile Durant; Pierre Pottier; François Perrin; Julie Graveleau; Mohamed Hamidou; Jean-Benoit Hardouin; Christian Agard
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-05-18       Impact factor: 5.346

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.